No announcement yet.


  • Filter
  • Time
  • Show
Clear All
new posts

  • Tuberculosis

    The Lancet 2003; 362:887-899

    Dr Thomas R FriedenMD a , Timothy R SterlingMD b, Sonal S MunsiffMD c, Catherine J WattDPhil d and Christopher DyeDPhil d

    Genetic predisposition
    Clinical manifestations
    BCG vaccination
    Search strategy and selection criteria


    Among communicable diseases, tuberculosis is the second leading cause of death worldwide, killing nearly 2 million people each year. Most cases are in less-developed countries; over the past decade, tuberculosis incidence has increased in Africa, mainly as a result of the burden of HIV infection, and in the former Soviet Union, owing to socioeconomic change and decline of the health-care system. Definitive diagnosis of tuberculosis remains based on culture for Mycobacterium tuberculosis, but rapid diagnosis of infectious tuberculosis by simple sputum smear for acid-fast bacilli remains an important tool, and more rapid molecular techniques hold promise. Treatment with several drugs for 6 months or more can cure more than 95% of patients; direct observation of treatment, a component of the recommended five-element DOTS strategy, is judged to be the standard of care by most authorities, but currently only a third of cases worldwide are treated under this approach. Systematic monitoring of case detection and treatment outcomes is essential to effective service delivery. The proportion of patients diagnosed and treated effectively has increased greatly over the past decade but is still far short of global targets. Efforts to develop more effective tuberculosis vaccines are under way, but even if one is identified, more effective treatment systems are likely to be required for decades. Other modes of tuberculosis control, such as treatment of latent infection, have a potentially important role in some contexts. Until tuberculosis is controlled worldwide, it will continue to be a major killer in less-developed countries and a constant threat in most of the more-developed countries.
    Back to top

    Tuberculosis has probably killed 100 million people over the past 100 years,1 although a cure was available for the second half of the 20th century. This review summarises the current status of tuberculosis epidemiology, pathophysiology, diagnosis, treatment, and control. Although most cases of tuberculosis occur in less-developed countries, this review is relevant to both more-developed and less-developed countries.

    Tuberculosis is the world's second commonest cause of death from infectious disease, after HIV/AIDS. There were an estimated 8?9 million new cases of tuberculosis in 2000, fewer than half of which were reported; 3?4 million cases were sputum-smear positive, the most infectious form of the disease.2 Most cases (5?6 million) are in people aged 15?49 years. Sub-Saharan Africa has the highest incidence rate (290 per 100 000 population), but the most populous countries of Asia have the largest numbers of cases: India, China, Indonesia, Bangladesh, and Pakistan together account for more than half the global burden. 80% of new cases occur in 22 high-burden countries (figure 1).

    Click to enlarge image

    Figure 1. Estimated number of new tuberculosis cases by country, 2001

    The global tuberculosis caseload appears to be growing slowly. Case numbers have declined more or less steadily in western and central Europe, North and South America, and the Middle East. By contrast, there have been striking increases in countries of the former Soviet Union and in sub-Saharan Africa (figure 2).3

    Click to enlarge image

    Figure 2. Trends and projections in numbers of tuberculosis cases to 2010 for countries of eastern and southern Africa with high HIV prevalence, and in the former Soviet UnionBroken lines indicate 95% CI. Adapted with permission from WHO global tuberculosis report 2003, based on trends in notification rates.3

    Tuberculosis rates have increased in the former Soviet Union because of economic decline and the general failure of tuberculosis control and other health services since 1991.4 Periodic surveys have shown that more than 10% of new tuberculosis cases in Estonia, Latvia, and some parts of Russia are multi-drug resistant5?ie, resistant to at least isoniazid and rifampicin, the two most effective antituberculosis drugs. However, resistance is a byproduct of tuberculosis resurgence in these countries, not the primary cause of it.
    HIV infection accounts for much of the recent increase in the global tuberculosis burden.2 Worldwide, an estimated 11% of new adult tuberculosis cases in 2000 were infected with HIV, with wide variations among regions: 38% in sub-Saharan Africa, 14% in more developed countries, and 1% in the Western Pacific Region. Rates of HIV infection among patients with tuberculosis have so far remained below 1% in Bangladesh, China, and Indonesia. The increase in tuberculosis incidence in Africa is strongly associated with the prevalence of HIV infection.6 Rates of HIV infection among tuberculosis patients are correspondingly high, exceeding 60% in Botswana, South Africa, Zambia, and Zimbabwe. About two million people died of tuberculosis in 2000; about 13% of these people were also infected with HIV.2
    Back to top

    Tuberculosis is spread by airborne droplet nuclei, which are particles of 1?5 μm in diameter that contain Mycobacterium tuberculosis. Because of their small size, the particles can remain airborne for minutes to hours after expectoration by people with pulmonary or laryngeal tuberculosis during coughing, sneezing, singing, or talking.7?9 The infectious droplet nuclei are inhaled and lodge in the alveoli in the distal airways. M tuberculosis is then taken up by alveolar macrophages, initiating a cascade of events that results in either successful containment of the infection or progression to active disease (primary progressive tuberculosis). Although the risk of development of active disease varies according to time since infection, age, and host immunity, the estimated lifetime risk of disease for a newly infected young child is 10%, with roughly half of that risk occurring in the first 2 years after infection.10,11
    After being ingested by alveolar macrophages, M tuberculosis replicates slowly but continuously and spreads via the lymphatic system to the hilar lymph nodes. In most infected individuals, cell-mediated immunity develops 2?8 weeks after infection. Activated T lymphocytes and macrophages form granulomas that limit further replication and spread of the organism.12M tuberculosis is in the centre of the characteristically necrotic (caseating or cheese-like) granulomas, but it is usually not viable. Unless there is a subsequent defect in cell-mediated immunity, the infection generally remains contained and active disease may never occur.
    The development of cell-mediated immunity against M tuberculosis is associated with the development of a positive result in the tuberculin skin test. At the cellular level, an effective host immune response occurs as follows. Alveolar macrophages infected with M tuberculosis interact with T lymphocytes via several important cytokines. The infected macrophage releases interleukins 12 and 18, which stimulate T lymphocytes (predominantly CD4-positive T lymphocytes) to release interferon γ.13,14 This cytokine, in turn, stimulates the phagocytosis of Mtuberculosis in the macrophage.
    Interferon γ does not directly stimulate the killing of M tuberculosis by the macrophage, at least partly because the organism inhibits the cytokine's transcriptional responses.15 Interferon γ is, however, crucial for the control of M tuberculosis infection,16 and it also stimulates the macrophage to release tumour necrosis factor α, which is important in granuloma formation and control of the extent of infection.17,18 The T-lymphocyte response is antigen specific and is influenced by the major histocompatibility complex.12,19 Although several M tuberculosis antigens have been identified, none confer protective immunity and they are thus unsuitable for a vaccine.
    When the host immune response cannot contain the replication of M tuberculosis associated with initial infection, active disease occurs. This development is most common in children under 5 years old and adults with advanced immunosuppression (eg, AIDS). This primary progressive disease can manifest in almost any organ system, but it occurs most frequently in the parenchyma of the mid and lower lung, in the hilar lymph nodes, or as generalised lesions resulting from haematogenous dissemination.1
    Although an effective host immune response can initially contain M tuberculosis infection, several factors can trigger subsequent development of active disease from reactivation of remote infection. HIV is the greatest single risk factor for progression to active disease in adults. Other medical conditions that can also compromise the immune system and predispose to development of active disease include poorly controlled diabetes mellitus, renal failure, underlying malignant disease, chemotherapy, extensive corticosteroid therapy, malnutrition, and deficiency of vitamin D or A.20?22 Defects in the production of interferon γ13,23 or tumour necrosis factor α24,25 as well as in the interferon-γ receptor26 and interleukin-12 receptor β 1, have also been described.27
    Back to top
    Genetic predisposition

    Several studies have suggested that some patients have a genetic predisposition to tuberculosis. This idea has arisen from studies among monozygotic and dizygotic twins28 and in an assessment of tuberculosis risk according to ancestral history.29 Population-based studies have found an association between tuberculosis and some HLA alleles, as well as polymorphisms in the genes for natural resistance-associated macrophage protein (NRAMP1), the vitamin D receptor, and interleukin 1.30?35 Although the functional importance of most of these polymorphisms is unclear, NRAMP1 polymorphisms could influence tuberculosis susceptibility by regulation of interleukin 10.36 Associations between genetic polymorphisms and tuberculosis susceptibility differ according to ethnic origin,37 but the extent to which genetic polymorphisms contribute to the global tuberculosis burden is unclear because of the great difficulty of separating lifelong environmental influences from genetic predisposition.
    Back to top
    Clinical manifestations

    The most common clinical manifestation of tuberculosis is pulmonary disease. Extrapulmonary tuberculosis accounts for about 20% of disease in HIV-seronegative people but is more common in HIV-seropositive individuals.38 Among people not infected with HIV, extrapulmonary disease, particularly lymphatic tuberculosis, is particularly common in women and young children.39,40
    Pleural tuberculosis occurs as a result of either primary progressive M tuberculosis infection or reactivation of latent infection. A chest radiograph generally reveals a unilateral pleural effusion. Unlike other clinical manifestations of tuberculosis, pleural disease probably represents an increased, rather than diminished, immune response. In fact, primary serofibrinous pleural effusion resolves without treatment in up to 90% of cases; however, if untreated, nearly two-thirds of patients will subsequently have relapses with tuberculosis at other organ sites.41
    The most serious clinical manifestation of tuberculosis is involvement of the central nervous system. Such involvement can include inflammation of the meninges, as well as space-occupying lesions (tuberculomas) of the brain. The clinical manifestations are due to the presence of M tuberculosis as well as the inflammatory host immune response. Children under 5 years of age and HIV-infected individuals are at increased risk of tuberculous meningitis,42,43 which can present clinically as chronic meningitis, with headache, fever, and changed mental status. Neurological manifestations can include cranial-nerve palsies and motor, sensory, and cerebellar defects, according to the location of the tuberculomas; seizures can also occur. Meningitis is fatal in almost all cases without chemotherapy, and prompt identification and treatment are essential to prevent serious neurological sequelae.
    Tuberculosis can affect any bone or joint, but the spine (ie, Pott's disease) is the most common bony structure involved. In the spine, the most common location is the thoracic section. Vertebral-body involvement can be followed by disease of an adjacent intervertebral disc.1
    Genitourinary tuberculosis (including involvement of the renal and male and female genital tracts) is uncommon and is difficult to distinguish from other infections of the genitourinary tract. In men, manifestations include those of prostatitis or prostate enlargement, epididymitis, and orchitis, but disease can also present as a painless scrotal mass. Urine analysis may show red or white blood cells, or both, with a negative urine culture for bacteria (sterile pyuria). In women, genitourinary tuberculosis is an important cause of infertility in areas with high tuberculosis incidence.44
    Disseminated tuberculosis is defined as involvement of many organs simultaneously and can occur as a result of primary progressive disease or reactivation of latent infection. The clinical manifestation of pulmonary involvement is a miliary (millet seed) pattern rather than an infiltrate in most cases, but not all patients with disseminated disease have pulmonary involvement. Mortality is high despite chemotherapy and may be related to delays in diagnosis and other commonly present underlying medical conditions.39
    Back to top

    Active disease

    Criteria for the diagnosis of active tuberculosis vary according to the setting. Patients with persistent cough (eg, lasting longer than 2 weeks) should be assessed for tuberculosis.45,46 Other common symptoms include fever, night sweats, weight loss, shortness of breath, haemoptysis, and chest pain.47 Among children, important diagnostic clues are a history of previous exposure to an individual with tuberculosis or evidence of tuberculosis infection (eg, a positive tuberculin skin test). To improve the diagnostic yield in children, diagnostic algorithms and point scoring systems are often used, particularly in less-developed countries.48
    Tests for the diagnosis of tuberculosis vary in sensitivity, specificity, speed, and cost. Even if additional tests are done, however, culture is required for definite diagnosis and is essential for drug-susceptibility testing. The sputum smear is an inexpensive test that can be carried out rapidly; fluorochrome, Ziehl-Neelsen, and Kinyoun staining methods can be used. The International Union Against Tuberculosis and Lung Disease (IUATLD) and WHO recommend the Ziehl-Neelsen method under most circumstances.46,49 Although the smear is positive in only 50?80% of individuals with culture-confirmed pulmonary tuberculosis, cases with organisms on the smear are more infectious than smear-negative cases and have higher case-fatality rates.50,51 Nonetheless, smear-negative disease accounts for 15?20% of M tuberculosis transmission.51,52 In countries with a high prevalence of tuberculosis, a positive direct smear is due to M tuberculosis in more than 95% of patients suspected of having tuberculosis;53 routine cultures are generally neither practicable nor necessary for disease control. Non-tuberculous mycobacteria, particularly in HIV-infected patients, tend to be present in much lower concentrations and are therefore rarely seen on a direct sputum smear. Concentrated smears (ie, those made from samples that have been decontaminated, liquefied, and centrifuged) may be more sensitive and are routinely used in laboratories that also routinely culture all specimens, because decontaminated and concentrated specimens are needed for culturing.49,54 In less-developed countries, a diagnostic algorithm for sputum-smear-negative patients is commonly used, based on response to antibiotics and results of chest radiography.
    Although the organism can take 6 weeks or longer to grow on solid culture media (eg, the egg-based Lowenstein-Jensen medium or the agar-based Middlebrook 7H10 or 7H11), growth generally occurs within 7?21 days with liquid culture media.55 Ideally, when cultures are done, both solid and liquid culture media should be used, because the former allow examination of colony morphology and the identification of mixed cultures, and the latter enable more rapid diagnosis.
    Radiographic findings suggesting tuberculosis include upper-lobe infiltrates, cavitary infiltrates, and hilar or paratracheal adenopathy. In many patients with primary progressive disease and those with HIV infection, radiographic findings are more subtle and can include lower-lobe infiltrates or a miliary pattern. HIV-infected patients, particularly those late in the course of HIV infection, generally experience greater weight loss and fever but are less likely to have cavitary disease and positive smears for acid-fast bacilli56 than those not infected with HIV, and in one study, 8% of HIV-infected patients with pulmonary tuberculosis had normal chest radiographs.57
    About 15?20% of adults with tuberculosis (on the basis of clinical, radiographic, and histopathological findings, as well as response to antituberculosis treatment)47 have negative sputum cultures. Among children, the proportion of culture-negative cases is much higher. False-positive cultures can also occur; in a review of 12 studies that assessed more than 100 patients and used DNA fingerprinting, the median false-positive rate was 2?9% (range 0?33%).58 False-positive results can be due to laboratory cross-contamination, contamination of clinical devices, or clerical errors, and are more common with liquid culture media.59 Where resources permit, there should be close scrutiny of cases with no positive smear, only one positive culture, and several negative cultures; selective use of DNA fingerprinting should be considered to rule out a false-positive culture.
    Where resources for diagnosis and treatment of drug-resistant tuberculosis allow, drug-susceptibility testing should ideally be done on all initial M tuberculosis isolates.47 Susceptibility testing should also be considered when cultures remain positive after 3 months of treatment, or become positive after being previously negative. Agar-based methods have been standard, although broth-based media are faster.60 Rapid detection of rifampicin resistance is particularly important, and new methods to detect this and other types of resistance are coming into clinical practice.61?64 Direct susceptibility testing on agar plates is a highly accurate technique for patients with heavily smear-positive tuberculosis. This technique requires technical expertise, but it can provide first-line and second-line susceptibility results in 10?14 days.65
    Nucleic-acid amplification assays can be used directly on clinical specimens; they are most reliable in smear-positive respiratory samples from patients with previously untreated tuberculosis. In such samples, the sensitivity and specificity can be as high as 95% and 98%, respectively. The sensitivity is 48?53% in smear-negative respiratory samples, but the specificity is roughly 95%.47,66 In areas of high tuberculosis prevalence, there is no need to confirm a heavily positive sputum smear, which will in most cases reflect M tuberculosis. However, where concentrated smears are used and either the prevalence of HIV is high or the prevalence of tuberculosis is low, amplification techniques can be useful in distinguishing positive smears due to M tuberculosis from positive smears with other mycobacteria.
    Widespread implementation of nucleic-acid amplification assays has been limited by high cost and potential for poor performance under field conditions. Amplification tests do not replace the sputum smear (which provides a gauge of infectiousness) or culture (which is necessary for drug-susceptibility testing). The assays can still give positive results after effective treatment (because of detection of residual genetic material), so they may not be as useful in people with previous disease or in monitoring response to therapy.
    In addition to advances in clinical laboratory tests, research methods of DNA fingerprinting can be useful to identify laboratory cross-contamination and elucidate the epidemiology of tuberculosis.67

    Latent infection

    The intradermal administration of tuberculin has been used as a diagnostic test for tuberculosis infection since the early 1900s;68 the more consistent form of tuberculin, standardised purified protein derivative (PPD-S), has been used to assess latent M tuberculosis infection since 69,70 Although the tuberculin skin test is the best available way to diagnose latent M tuberculosis infection, it has limitations, including low sensitivity in immunocompromised patients, cross-reactivity with bacille Calmette-Guerin (BCG) vaccine and environmental mycobacteria (resulting in decreased specificity), and a requirement that patients must return 48?72 h after the test is done to have the result read.71 The criteria for a positive test vary according to the population group being tested; they are influenced by the likelihood of being infected with M tuberculosis and the risk of developing active disease if infected.20
    A whole-blood interferon-γ release assay (IGRA), like the tuberculin skin test, assesses cell-mediated immunity to tuberculin.72 The correlation between the IGRA and the tuberculin skin test has been low.73,74 IGRA responses are diminished in HIV-infected individuals, resulting in low sensitivity in this important population,75 but they may aid in detecting latent infection among certain populations who are at increased risk (eg, recent migrants from countries with high incidence of tuberculosis).72 Although the IGRA is less sensitive and specific than the tuberculin skin test,74 responses are less affected by previous BCG vaccination.76 An enzyme-linked immunospot (ELISPOT) assay has recently been developed that is relatively sensitive and specific in detecting latent M tuberculosis infection.77
    Back to top


    The goals of treatment are to ensure cure without relapse, to prevent death, to stop transmission, and to prevent the emergence of drug resistance. M tuberculosis can remain dormant for long periods. The number of tubercle bacilli varies widely with the type of lesion, and the larger the bacterial population, the higher the probability that naturally resistant mutants are present even before treatment is started.78 Long-term treatment with a combination of drugs is required.79 Treatment of active tuberculosis with a single drug should never be attempted, and a single drug should never be added to a failing regimen.1,80
    Almost all recommended treatment regimens have two phases,81,82 on the basis of extensive evidence from controlled clinical trials. There is an initial intensive phase designed to kill actively growing and semidormant bacilli. This action shortens the duration of infectiousness with rapid smear and culture conversion after 2?3 months of treatment, in most cases (80?90%).83 At least two bactericidal drugs, isoniazid and rifampicin, are necessary in the initial phase. Pyrazinamide given in the initial intensive phase allows the duration of treatment to be reduced from 9 to 6 months, but it offers no benefit if given past the second month to patients with drug-susceptible tuberculosis.84 The addition of ethambutol benefits the regimen when initial drug resistance may be present or the burden of organisms is high.
    Several studies have shown that reliable prediction of which patients will take all prescribed medication by themselves is not possible;85 only direct observation can ensure that all drugs are taken. Directly observed treatment, in which a trained observer personally observes each dose of medication being swallowed by the patient, can ensure high rates of treatment completion, reduce development of acquired drug resistance, and prevent relapse.86?88 Non-adherence to tuberculosis treatment is known to have been common ever since the advent of chemotherapy in the 1950s.85 Thus, most tuberculosis treatment trials since that time have been carried out with direct observation.89 Randomised controlled trials have not shown a benefit from treatment observation; however, these trials have had a common shortcoming of less than optimum implementation of treatment observation, with rates of treatment success significantly below those of worldwide programmes of DOTS.90 Direct observation by trained individuals is the standard of practice in most countries3 and is a component of the five-point DOTS strategy recommended by WHO and IUATLD.45,46,81 Family members should not be relied on to ensure treatment completion.91,92 However, direct observation is only one feature of comprehensive tuberculosis care; sensitive, patient-centred treatment that includes direct observation is crucial for cure of patients and success of the programme.
    The initial phase of regimens including rifampicin should always be directly observed to ensure adherence and prevent emergence of resistance to rifampicin. The continuation phase eliminates most residual bacilli and reduces numbers of failures and relapses. At the start of the continuation phase there are low numbers of bacilli and less chance that drug-resistant mutants will be selected, and therefore fewer drugs are needed.83,89
    Standard treatment regimens

    WHO-recommended treatment regimens are shown in table 1. For each patient, the recommended regimen depends on the treatment category, which is based on severity of disease and history of previous treatment. For some forms of disease, such as tuberculous meningitis, disseminated tuberculosis, and spinal tuberculosis with neurological involvement, a 7?10-month continuation phase with isoniazid and rifampicin is often recommended.45

    Click to view table

    Table 1. WHO-recommended treatment regimens

    There are slight differences in the recommendations of the US Centers for Disease Control and Prevention and the American Thoracic Society (CDC/ATS), and the UK Joint Tuberculosis Committee of the British Thoracic Society (BTS) and WHO and IUATLD.45,46,81,82 WHO, IUATLD, and the BTS do not recommend twice-weekly dosing, although this is one recommendation in the USA. The 8-month regimen (2 months of HRZE/6 months of HE) is not recommended in the USA or the UK. The UK and US guidelines recommend use of the same 6-month rifampicin-based regimens for both smear-positive and smear-negative pulmonary tuberculosis.
    The recommended drug doses differ also; WHO recommends doses that are generally lower than those recommended by other authorities and which are supported by clinical trials, although the lower doses appear to have been safe and effective in large-scale treatment. Tables 2 and 3 give recommendations on dosing and monitoring, along with information on common and major adverse events for the standard drugs. Detailed information on adverse effects and their management is available from several excellent resources.45,93?96

    Click to view table

    Table 2. Doses, route of administration, and mode of action of primary drugs used in the treatment of tuberculosis

    Click to view table

    Table 3. Major adverse reactions and recommended regular monitoring of primary drugs used in the treatment of tuberculosis

    Extrapulmonary tuberculosis

    In most cases of extrapulmonary tuberculosis there are many fewer organisms present.97 In general, regimens used for pulmonary tuberculosis are effective in the treatment of extrapulmonary tuberculosis.98?102 WHO recommends classification of the disease into severe and non-severe forms. Severe forms include meningeal and central-nervous-system tuberculosis, spinal tuberculosis, abdominal tuberculosis, bilateral pleural effusion, pericardial effusion, and bone and joint tuberculosis involving more than one site. WHO recommends category I regimens for severe forms and category III regimens for non-severe forms.45 All major organisations agree that some forms of disease, such as meningitis, may benefit from a longer treatment course.45,81,82 Steroids should be used for patients with large pleural effusions, pericardial disease, and meningitis, particularly with neurological impairment, since these drugs are likely to decrease morbidity and mortality in such cases.103?110

    Treatment in pregnant and breastfeeding women

    Isoniazid, rifampicin, pyrazinamide, and ethambutol are not teratogenic,111 and WHO recommends their use in women who are pregnant.45 In the USA, pyrazinamide is not recommended for use during pregnancy except when alternative drugs are not available or are less effective.81 Active tuberculosis in pregnancy must be treated, because untreated disease will harm the mother and the unborn child more than standard drugs would. However, some reserve drugs may be more toxic (table 4); the risks and benefits of these drugs must be assessed for each woman separately, and in some instances treatment with reserve drugs should bedeferred.

    Click to view table

    Table 4. Reserve drugs used in the treatment of tuberculosis: doses, major adverse reactions, and recommended regular monitoring

    Most antituberculosis drugs can be used during breastfeeding.113 No data are available for ethionamide. Although data are lacking on amikacin and capreomycin, they are likely to be safe given their structural similarity to streptomycin and kanamycin (which are considered safe). Concentrations of antituberculosis drugs in breastmilk are too low to prevent or treat tuberculosis in infants. If tuberculosis is suspected in the child, he or she should be treated.

    Treatment in patients with liver disease

    Drug-induced hepatitis can be fatal.93,94 WHO recommends that pyrazinamide should not be used in patients with known chronic liver disease. In decompensated liver disease, a regimen without rifampicin can be used.45 Streptomycin, ethambutol, and a reserve drug such as a fluoroquinolone can be used if treatment is necessary in patients with fulminant liver disease.81

    Treatment of patients with renal failure

    Normal doses of isoniazid, rifampicin, and pyrazinamide can be given in renal failure, since these drugs are eliminated almost entirely by biliary excretion or are metabolised into non-toxic compounds.114 In severe renal failure, patients receiving isoniazid should also receive pyridoxine to prevent peripheral neuropathy. Ethambutol can accumulate and cause optic neuropathy.112 Recommendations on the use of the other drugs in patients with renal failure are given in table 5. Individuals on haemodialysis should receive primary drug treatment by direct observation after dialysis; several of the drugs are eliminated during dialysis.115,116

    Click to view table

    Table 5. Use of antituberculosis drugs during pregnancy, tuberculous meningitis, and renal and hepatic failure

    Treatment of HIV-infected patients

    Recommended treatment regimens are similar for HIV-infected and HIV-negative tuberculosis patients. However, thioacetazone should never be used, because it is associated with an increased risk of severe and in some cases fatal skin reactions in HIV-infected individuals.117,118 In addition, response to treatment and survival are better in HIV-infected patients treated with short-course treatment including rifampicin than with other regimens that do not include rifampicin.118,119 Therefore, all attempts should be made to use directly observed rifamycin-based regimens.
    The clinical, radiographic, and microbiological responses to short-course treatment are similar irrespective of HIV status, although death during antituberculosis treatment is much more common in HIV-infected individuals.120?122 There is evidence that direct observation of treatment is even more important for HIV-infected patients, and it is considered the standard of 121,123 Several studies have found that, although relapse rates are low, they are higher than in HIV-negative individuals, care124?126 whereas other studies have found similar relapse rates in HIV-infected and HIV-negative individuals.127,128 Others have identified reinfection rather than relapse as a common cause of recurrence of tuberculosis in HIV-infected patients in areas with high incidence of tuberculosis.129 Clinical suspicion of recurrence of disease, due to relapse or reinfection, should be high in HIV-infected patients who have completed treatment.
    Several antiretroviral drugs (ie, most protease inhibitors and non-nucleoside reverse transcriptase inhibitors except efavirenz) should not be used with rifampicin.130 Rifabutin has similar activity against M tuberculosis,131?133 has less effect on the pharmacokinetics of some antiretroviral drugs, and is recommended in the USA as an equivalent alternative agent for HIV-infected patients receiving certain antiretroviral drugs.134?136 There are concerns that patients with less than 100 CD4-positive cells per μL who are treated with highly intermittent regimens may have a higher risk of relapsing with acquired rifampicin resistance. Therefore, twice-weekly therapy with any rifamycin-based regimen is not recommended for HIV-infected individuals with less than 100 CD4-positive cells per μL.137
    Rifapentine is a rifamycin derivative with a long half-life and its activity against M tuberculosis is similar to that of rifampicin. It is not recommended in HIV-infected patients because of increased risk of acquired rifampicin resistance.138 It has not been studied in patients with extrapulmonary tuberculosis. Rifapentine is recommended in the USA in the continuation-phase treatment of HIV-negative patients with non-cavitary pulmonary disease.81 Most but not all strains resistant to rifampicin are resistant to rifabutin and rifapentine.
    Paradoxical worsening of tuberculosis (defined as increased fever, worsening of pulmonary infiltrates, or new clinical manifestations of disease) can occur in patients on effective treatment. Although described in both HIV-seronegative and HIV-seropositive patients, it may be more common in the latter.139?141 The underlying pathophysiology of paradoxical worsening is not well understood, but it probably involves increased recognition of mycobacterial antigens resulting from improved immune function.142 Other possible causes of the signs and symptoms should be excluded; these include drug failure, drug resistance, non-adherence, and other diseases such as lymphoma. Paradoxical worsening can occur after initiation of tuberculosis treatment or can be associated with the initiation of antiretroviral therapy in HIV-infected patients with tuberculosis.139,143

    Management of drug-resistant cases

    The treatment of patients whose organisms are resistant to standard drugs or who do not tolerate them is difficult. Reserve drugs are generally less effective and more toxic than standard therapy; they must be given daily, and some need to be taken several times a day.45,80
    When devising a regimen for suspected or confirmed drug-resistant disease, several important principles must be followed. The initial regimen should include at least three drugs to which the bacilli are likely to be fully susceptible. Drugs should not be kept in reserve; the regimen most likely to be effective should be prescribed. Second-line drugs should be given daily under direct observation. Bacteriological results (smear and, if possible, culture) should be monitored.45,80
    If susceptibility test results are available, a regimen can be chosen, based on the drugs to which the strain of M tuberculosis is susceptible. Most authorities recommend three or four oral drugs plus one injectable drug (such as capreomycin, amikacin, or kanamycin) to which the isolate is susceptible for 3?6 months, and then at least three effective oral drugs for 15?18 months, for a total of 12?18 months after culture conversion to negative.45,80
    All efforts should be pursued to obtain an accurate susceptibility profile in patients for whom a standard regimen with first-line drugs fails, particularly if the treatment was given under direct observation. If drug-susceptibility testing is not available, standard retreatment regimens can be used. Decisions must take into account the regimens the patient has received before, and whether the previous regimens were fully administered under direct observation and for how long. Longer use of injectable drugs is associated with improved outcomes,144 but long-term administration is commonly complicated by ototoxicity, nephrotoxicity, and local adverse reactions (eg, pain, induration, abscess formation). Details on the doses and major common adverse effects for the reserve drugs are given in table 4.
    Back to top


    To control tuberculosis, WHO and IUATLD recommend the DOTS strategy,145 which has five elements: political commitment, diagnosis primarily by sputum-smear microscopy among patients attending health facilities, short-course treatment with effective case management (ie, direct observation), regular drug supply, and systematic monitoring to assess outcomes of every patient started on treatment. Standard short-course regimens can cure more than 95% of cases of new, drug-susceptible tuberculosis. DOTS should be used as the basis for more complex tuberculosis-control strategies where rates of drug resistance or HIV infection are high. The international targets for tuberculosis control by 2005 are to detect 70% of new pulmonary smear-positive cases annually, and to treat 85% of detected cases successfully.146
    Many of the 155 national DOTS programmes in existence by the end of 2001 have shown that they can achieve high cure rates: average treatment success was 82%, not far below the 85% target,3 with lower rates in Africa (72%) and some countries of the former Soviet Union (eg, 68% in the Russian Federation). However, only 32% of all estimated new smear-positive cases were treated under DOTS programmes in 2001.3 The increase in case notifications under DOTS has been steady since 1995 (figure 3); if the current rate of progress in DOTS expansion is maintained, the target of 70% case detection will not be reached until after 2010. However, there is a risk that progress will be slower: if DOTS programmes fail to reach beyond traditional public-health systems, they may never be able to detect more than the 50% of cases currently notified to WHO (figure 3).147

    Click to enlarge image

    Figure 3. Observed and projected rate of detection of smear-positive cases compared with the 70% global targetThe lower set of points is derived from case notifications submitted to WHO by DOTS programmes divided by the estimated incidence rate for these countries. Linear projection of the trend observed from 1995 to 2001 (blue line) indicates that, if the trend is maintained, 70% case detection will be reached in 2012. To reach 70% case detection by 2005, case finding must be significantly accelerated (red line). The upper set of points represent all smear-positive cases notified to WHO from all sources, including DOTS and non-DOTS programmes. Observations on the implementation of DOTS suggest that case-detection rates may reach a maximum of less than 50%, indicated by the broken line, unless case detection improves. Adapted with permission from Dye et al.147

    Both mathematical modelling and practical experience suggest that, if case-detection and cure rates can be increased to 70% and 85%, respectively, tuberculosis incidence will decline at 5?10% per year in areas of high incidence and in the absence of HIV.148,149 At a 7% annual decline, incidence would be halved in 10 years. In Peru, where DOTS was introduced in 1990, high rates of case detection and cure have decreased the incidence of pulmonary tuberculosis by at least 6% per year (figure 4).150

    Click to enlarge image

    Figure 4. Notified pulmonary tuberculosis cases per 100 000 population, Peru, 1980?2000The DOTS strategy was introduced in 1990, and the incidence of pulmonary tuberculosis has been falling at an average of 6% per year since 1996. Adapted with permission from Su?rez et al.150

    With effective treatment, tuberculosis mortality typically falls faster than case numbers. Thus, incidence in the Netherlands decreased at an average of 7% per year between 1950 and 1995, but the death rate fell more than 12% annually.149 Indirect assessments of the effect of DOTS suggest that hundreds of thousands of lives have been saved in China and India.151,152
    Where the prevalence of HIV infection is high, as in eastern and southern Africa, tuberculosis treatment alone will not be able to reverse the rise in incidence of tuberculosis. At present, the most effective way to address HIV-associated tuberculosis is via a sound DOTS programme coupled with comprehensive, effective HIV prevention and care.153,154
    Back to top
    BCG vaccination

    Randomised and case-control trials have shown consistently high protective efficacy (mostly above 70%) of BCG against serious forms of disease in children (meningitis and miliary tuberculosis), but variable efficacy against pulmonary tuberculosis in adults.155 Thus, in high-prevalence areas, vaccination is recommended for children at birth or at first contact with health services, except for children with symptomatic HIV infection.156 Even with high coverage, BCG has not had any substantial effect on transmission or incidence, because its main action is to prevent serious (but non-infectious) disease in children.157 Adverse events from BCG vaccination can occur, including local subcutaneous abscess and ulcers, suppurative lymphadenitis, and, more rarely, disseminated disease.158
    Despite continuing efforts to develop more effective tuberculosis vaccines, none have been identified to date. Even if one were to be developed, it might not prevent progression to active disease among the more than 2 billion people already infected with M tuberculosis. Therefore, even if a new vaccine were to be implemented worldwide, more effective treatment systems would be required for decades.
    Treatment of latent tuberculosis infection

    Treatment of latent infection has generally consisted of daily administration of isoniazid for 6?12 months. Such treatment is 60?90% effective in reducing the risk of progression from tuberculosis infection to disease.159 HIV-infected, tuberculin-positive individuals can benefit greatly from treatment of latent tuberculosis infection, if practical aspects of programme administration can be addressed. Contacts of active cases (especially children), recent converters to tuberculin skin test positivity, and selected individuals at high risk of disease can also benefit.20 Recent trials have shown that drug combinations, particularly rifampicin and pyrazinamide for 2?3 months, can be as effective as 12 months of isoniazid but are not as safe.160?162
    Long-term isoniazid treatment, although safe and reasonably cheap, cannot easily be administered to the large number of infected people who are at low risk of developing tuberculous disease. In the coming years, treatment of latent tuberculosis infection will be used more frequently to prevent tuberculosis among HIV-infected individuals even though, in areas of high transmission, protection may not extend for more than 2?3 years beyond the end of treatment, and there is at most a short prolongation of life.163?165
    Back to top


    The current state of tuberculosis diagnosis, treatment, and control reveals striking contrasts. On the one hand, new diagnostic methods have been developed, and widespread application of control strategies has increased the number of patients effectively diagnosed and treated annually from 696 000 in 1995 to 2?4 million in 2001 (all forms of tuberculosis treated under DOTS), with more than 10 million patients treated in the past 10 years. Effective tuberculosis control is both inexpensive and cost-effective.166 On the other hand, the mainstays of diagnosis remain the sputum smear and culture, both 100 years old. No new first-line drugs have been discovered for several decades, and two-thirds of patients who develop tuberculosis are not effectively diagnosed, treated, or monitored. The influence of HIV infection on the tuberculosis burden in eastern and southern Africa will be difficult to reverse without more effective HIV prevention and more widely available antiretroviral therapy in the less-developed countries. Further progress will require continued rigorous and dedicated application of current technology and will be greatly facilitated by the discovery and widespread application of new diagnostic techniques, drugs, and prevention strategies, such as an effective vaccine.
    Back to top
    Search strategy and selection criteria

    We searched PubMed/MEDLINE for articles with tuberculosis as major topic, and epidemiology, pathophysiology, diagnosis, treatment, or control as secondary topics. The Cochrane database was searched for reviews of tuberculosis. We also examined the websites and publications of the WHO, International Union Against Tuberculosis and Lung Disease, British Thoracic Society, American Thoracic Society, and US Centers for Disease Control and Prevention, as well as major current tuberculosis textbooks. Many other papers were found in the reference lists of articles identified through initial searches. The databases and publications were searched between April, 2002, and March, 2003. We did not limit the search to articles published in English, nor specifically to particular dates.

    Back to top
    Conflict of interest statement
    None declared.
    Role of the funding source
    TRS received funding from the National Institutes of Allergy and Infectious Diseases (k23 AIO1654). No other person or organisation provided any of the authors with funding related to the preparation of this article.

    We thank William Harris, senior consultant to the Bureau of Tuberculosis Control of the New York City Department of Health and Mental Hygiene, Mark Perkins of the UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases, and John A Jereb and Kenneth G Castro of the Centers for Disease Control and Prevention for their insights in reviewing this document, and Drew Blakeman for editorial preparation.
    Back to top

  • #2
    Re: Tuberculosis


    1. Iseman MD. A clinician's guide to tuberculosis. Philadelphia: Lippincott, Williams and Wilkins, 2000:.
    2. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021. MEDLINE | CrossRef
    3. World Health Organization. Global tuberculosis control: surveillance, planning, financing, WHO Report 2003 (WHO/CDS/TB/2003.316). Geneva: WHO, 2003:.
    4. Shilova MV, Dye C. The resurgence of tuberculosis in Russia. Philos Trans R Soc Lond Biol Sci 2001; 356: 1069-1075.
    5. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no 2. Prevalence and trends (WHO/CDS/TB/2000.278). Geneva: WHO, 2000:.
    6. Corbett EL, Steketee RW, ter Kuile FO, Latif AS, Kamali A, Hayes RJ. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002; 359: 2177-2187. Abstract | Full Text | PDF (143 KB) | MEDLINE | CrossRef
    7. Wells WF. On air-borne infection: study II, droplets and droplet nuclei. Am J Hygiene 1934; 20: 611-618.
    8. Louden RG, Roberts RM. Droplet expulsion from the respiratory tract. Am Rev Respir Dis 1966; 95: 435-442. MEDLINE
    9. Riley RL, Mills CC, Nyka W, et al. Aerial dissemination of pulmonary tuberculosis: a two-year study of contagion in a tuberculosis ward. Am J Hygiene 1959; 70: 185-196.
    10. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974; 99: 131-138. MEDLINE
    11. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976; 19: 1-63. MEDLINE
    12. Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med 1998; 157: 679-691. MEDLINE
    13. Sodhi A, Gong J, Silva C, Qian D, Barnes PF. Clinical correlates of interferon-gamma production in patients with tuberculosis. Clin Infect Dis 1997; 25: 617-620. MEDLINE
    14. Ellner JJ. Review: The immune response in human tuberculosis: implications for tuberculosis control. J Infect Dis 1997; 176: 1351-1359. MEDLINE
    15. Ting LM, Kim AC, Cattamanchi A, Ernst JD. Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1. J Immunol 1999; 163: 3898-3906. MEDLINE
    16. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon-gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178: 2249-2254. MEDLINE | CrossRef
    17. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2: 561-572. MEDLINE | CrossRef
    18. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162: 3504-3511. MEDLINE
    19. Flynn JL, Ernst JD. Immune responses in tuberculosis. Curr Opin Immunol 2000; 12: 432-436. MEDLINE | CrossRef
    20. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: S221-S247.
    21. Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355: 618-621. Abstract | Full Text | PDF (90 KB) | MEDLINE | CrossRef
    22. Karyadi E, West CE, Schultink W, et al. A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status. Am J Clin Nutr 2002; 75: 720-727. MEDLINE
    23. Hirsch CS, Toossi Z, Othieno C, et al. Depressed T-cell interferon-gamma responses in pulmonary tuberculosis: analysis of underlying mechanisms and modulation with therapy. J Infect Dis 1999; 180: 2069-2073. MEDLINE | CrossRef
    24. Sterling TR, Dorman SE, Chaisson RE, et al. HIV-seronegative adults with extrapulmonary tuberculosis have abnormal innate immune responses. Clin Infect Dis 2001; 33: 976-982. MEDLINE | CrossRef
    25. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104. MEDLINE | CrossRef
    26. Jouanguy E, Lamhamedi-Cherradi S, Altare F, et al. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guerin infection and a sibling with clinical tuberculosis. J Clin Invest 1997; 100: 2658-2664. MEDLINE
    27. Altare F, Ensser A, Breiman A, et al. Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. J Infect Dis 2001; 184: 231-236. MEDLINE | CrossRef
    28. Comstock GW. Tuberculosis in twins: a re-analysis of the Prophit survey. Am Rev Respir Dis 1978; 117: 621-624. MEDLINE
    29. Stead WW. Genetics and resistance to tuberculosis. Ann Intern Med 1992; 116: 937-941. MEDLINE
    30. Singh SP, Mehra NK, Dingley HB, Pande JN, Vaidya MC. Human leukocyte antigen (HLA)-linked control of susceptibility to pulmonary tuberculosis and association with HLA-DR types. J Infect Dis 1983; 148: 676-681. MEDLINE
    31. Goldfeld AE, Delgado JC, Thim S, et al. Association of an HLA-DQ allele with clinical tuberculosis. JAMA 1998; 279: 226-228. MEDLINE | CrossRef
    32. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998; 338: 640-644. MEDLINE | CrossRef
    33. Greenwood CM, Fujiwara TM, Boothroyd LJ, et al. Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. Am J Hum Genet 2000; 67: 405-416. MEDLINE | CrossRef
    34. Bellamy R, Ruwende C, Corrah T, et al. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis 1999; 179: 721-724. MEDLINE | CrossRef
    35. Wilkinson RJ, Patel P, Llewelyn M, et al. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J Exp Med 1999; 189: 1863-1874. MEDLINE | CrossRef
    36. Awomoyi A, Marchant A, Howson JMM, McAdam KP, Blackwell JM, Newport MJ. Interleukin-10, polymorphism in SLC11A1 (formerly NRAMP1), and susceptibility to tuberculosis. J Infect Dis 2002; 186: 1808-1814. MEDLINE | CrossRef
    37. Delgado JC, Baena A, Thim S, Goldfield AE. Ethnic-specific genetic associations with pulmonary tuberculosis. J Infect Dis 2002; 186: 1463-1468. MEDLINE | CrossRef
    38. Shafer RW, Edlin BR. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis 1996; 22: 683-704. MEDLINE
    39. Rieder HL, Snider DE Jr, Cauthen GM. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 1990; 141: 347-351. MEDLINE
    40. Rieder HL. Epidemiologic basis of tuberculosis control. Paris: International Union Against Tuberculosis and Lung Disease, 1999:.
    41. Roper WH, Waring JJ. Primary serofibrinous pleural effusion in military personnel. Am Rev Tuberc 1955; 71: 616-634. MEDLINE
    42. Thwaites G, Chau TT, Mai NT, Drobniewski F, McAdam K, Farrar J. Tuberculous meningitis. J Neurol Neurosurg Psychiatry 2000; 68: 289-299. MEDLINE | CrossRef
    43. Berenguer J, Moreno S, Laguna F, et al. Tuberculous meningitis in patients infected with the human immunodeficiency virus. N Engl J Med 1992; 326: 668-672. MEDLINE
    44. Goldfarb D, Saimn L. Tuberculosis of the genitourinary tract In: Rom WN, Garay S, eds. Tuberculosis. New York: Little Brown, 1996: 609-622.
    45. World Health Organization Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes. Geneva: WHO, 2003WHO/CDS/TB/2003.13)..
    46. Enarson DA, Rieder HL, Arnadottir T, Tr?bucq A. In: Management of tuberculosis: a guide for low-income countries. Paris: International Union Against Tuberculosis and Lung Disease, 2000: 1-89.
    47. American Thoracic Society, Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161: 1376-1395. MEDLINE
    48. Hesseling AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of diagnostic approaches used in the diagnosis of childhood tuberculosis. Int J Tuberc Lung Dis 2002; 6: 1038-1045. MEDLINE
    49. World Health Organization Global Tuberculosis Programme. Laboratory services in tuberculosis control (WHO/TB/98.258 [Pt 2]). Geneva: WHO, 1998:.
    50. Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954; 69: 724-732. MEDLINE
    51. Grzybowski S, Barnett GD, Syblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975; 50: 90-106. MEDLINE
    52. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353: 444-449. Abstract | Full Text | PDF (76 KB) | MEDLINE | CrossRef
    53. Crampin AC, Floyd S, Mwaungulu F, et al. Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence. Int J Tuberc Lung Dis 2001; 5: 994-999. MEDLINE
    54. Kubica G, Kent K. In: Public health mycobacteriology: a guide for the level III laboratory. Atlanta: Department of Health and Human Services, Public Health Service, Centers for Disease Control, 1985: 60-63.
    55. Morgan MA, Horstmeier CD, DeYoung DR, Robers GD. Comparison study of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol 1983; 18: 384-388. MEDLINE
    56. Harries AD, Maher D. TB/HIV: a clinical manual (WHO/TB/96.200: 38). Geneva: WHO, 1996:.
    57. Perlman DC, El Sadr WM, Nelson ET, et al. Variation of chest radiographic patterns in pulmonary tuberculosis by degree of human immunodeficiency virus-related immunosuppression. Clin Infect Dis 1997; 25: 242-246. MEDLINE
    58. Burman WJ, Reves RR. Review of false-positive cultures for Mycobacterium tuberculosis and recommendations for avoiding unnecessary treatment. Clin Infect Dis 2000; 31: 1390-1395. MEDLINE | CrossRef
    59. Nivin B, Fujiwara PI, Hannifin J, Kreiswirth BN. Cross-contamination with Mycobacterium tuberculosis: an epidemiological and laboratory investigation. Infect Control Hosp Epidemiol 1998; 19: 500-503. MEDLINE
    60. Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis 2000; 31: 1209-1215. MEDLINE | CrossRef
    61. Cooksey RC, Morlock GP, Glickman S, Crawford JT. Evaluation of a line probe assay kit for characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from New York City. J Clin Microbiol 1997; 35: 1281-1283. MEDLINE
    62. Jacobs WR Jr, Barletta RG, Udani R, et al. Rapid assessment of drug susceptibilities of Mycobacterium tuberculosis by means of luciferase reporter phages. Science 1993; 260: 819-822. MEDLINE
    63. Piatek AS, Tyagi S, Pol AC, et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotechnol 1998; 16: 359-363. MEDLINE | CrossRef
    64. Piatek AS, Telenti A, Murray MR, et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 2000; 44: 103-110. MEDLINE
    65. Heifets LB, Cangelosi GA. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999; 3: 564-581. MEDLINE
    66. American Thoracic Society. Rapid diagnostic tests for tuberculosis: what is the appropriate use?. Am J Respir Crit Care Med 1997; 155: 1804-1814. MEDLINE
    67. Behr MA, Small PM. Molecular fingerprinting of Mycobacterium tuberculosis: how can it help the clinician?. Clin Infect Dis 1997; 25: 806-810. MEDLINE
    68. Von Pirquet C. Frequency of tuberculosis in childhood. JAMA 1909; 52: 675-678.
    69. Seibert FB, Glen JT. Tuberculin purified protein derivative: preparation and analyses of a large quantity for standard. AmRevTuberc 1941; 44: 9-24.
    70. Lee E, Holzman RS. Evolution and current use of the tuberculin test. Clin Infect Dis 2002; 34: 365-370. CrossRef
    71. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. ClinInfect Dis 1993; 17: 968-975.
    72. Mazurek GH, Villarini ME. Guidelines for using the QuantiFeron-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2003; 52 (RR-2): 15-18.
    73. Kimura M, Converse PJ, Astemborski J, et al. Comparison between a whole blood interferon-gamma release assay and tuberculin skin testing for the detection of tuberculosis infection among patients at risk for tuberculosis exposure. J Infect Dis 1999; 179: 1297-1300. MEDLINE | CrossRef
    74. Bellete B, Coberly J, Barnes GL, et al. Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis 2002; 34: 1449-1456. CrossRef
    75. Converse PJ, Jones SL, Astemborski J, Vlahov D, Graham NM. Comparison of a tuberculin interferon-gamma assay with the tuberculin skin test in high-risk adults: effect of human immunodeficiency virus infection. J Infect Dis 1997; 176: 144-150. MEDLINE
    76. Mazurek GH, LoBue PA, Daley CL, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001; 286: 1740-1747. MEDLINE | CrossRef
    77. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361: 1168-1173. Abstract | Full Text | PDF (286 KB) | MEDLINE | CrossRef
    78. David HL. Probability distribution of drug resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20: 810-814. MEDLINE
    79. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946?1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3: S231-S279.
    80. Iseman MD. Treatment of multidrug-resistant tuberculosis. NEnglJMed 1993; 329: 784-791.
    81. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662. MEDLINE | CrossRef
    82. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53: 536-548. MEDLINE
    83. Girling DJ. The chemotherapy of tuberculosis In: Ratledge C, Stanford J, Grange JM, eds. Biology of the mycobacteria: clinical aspects of mycobacterial disease. Cambridge: Academic Press, 1989: 285-323.
    84. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampicin, and pyrazinamide: results at 30 months. AmRevRespir Dis 1991; 143: 700-706.
    85. Fox W. Compliance of patients and physicians: experience and lessons from tuberculosis I. BMJ 1993; 287: 33-35.
    86. Weis SE, Slocum PC, Blais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 334: 1179-1184.
    87. Chaulk PC, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998; 279: 943-947. MEDLINE | CrossRef
    88. Kamolratanakul P, Sawert H, Lertmaharit S, et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg 1999; 93: 552-557. MEDLINE | CrossRef
    89. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979; 76: S771-S781.
    90. Frieden TR. Directly observed treatment for tuberculosis. Lancet 1999; 353: 146. Full Text | PDF (45 KB) | MEDLINE | CrossRef
    91. Pungrassami P, Johnsen AP, Chongsuvivatwong V, Olsen J, Sorensen HT. Practice of directly observed treatment (DOT) in southern Thailand: comparison between different types of observers. Int J Tuberc Lung Dis 2002; 6: 389-395. MEDLINE
    92. Frieden T, Sbarbaro JA. The slippery slope to sloppy DOTS. Int J Tuberc Lung Dis 2002; 6: 371-372. MEDLINE
    93. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuberc Lung Dis 1996; 77: 37-42.
    94. Girling DJ. Adverse effects of antituberculosis drugs. Drugs 1982; 23: 56-74. MEDLINE
    95. Rieder HL. Interventions for tuberculosis control and elimination. Paris: International Union Against Tuberculosis and Lung Disease, 2002:.
    96. Bureau of Tuberculosis Control. Clinical polices and protocols. New York City Department of Health, 1999:
    Available from: URL:
    (accessed June 24, 2003)..
    97. Grosset J, Truffot-Pernot C, Cambau E. Bacteriology of tuberculosis In: Reichman LB, Hershfield ES, eds. Tuberculosis: a comprehensive international approach. New York: Marcel Dekker, 2000: 157-185.
    98. British Thoracic Society Research Committee. Short course chemotherapy for tuberculosis of lymph nodes: a controlled trial. BMJ 1985; 290: 1106-1108.
    99. MRC Working Party on Tuberculosis of the Spine. Five-year assessment of controlled trials of short-course chemotherapy regimens of 6, 9 or 18 months' duration for spinal tuberculosis in patients ambulatory from the start or undergoing radical surgery. Int Orthop 1999; 23: 73-81. MEDLINE | CrossRef
    100. Balasubramanian R, Ramachandran R. Management of non-pulmonary forms of tuberculosis: review of TRC studies over two decades. Indian J Pediatr 2000; 67: S34-S40.
    101. Yuen APW, Wong SHW, Tam CM, Chan SL, Wei WI, Lau AK. Prospective randomised study of thrice weekly six-month and nine-month chemotherapy for cervical tuberculous lymphadenopathy. Otolaryngol Head Neck Surg 1997; 116: 189-192. Abstract | Full Text | PDF (388 KB) | MEDLINE | CrossRef
    102. Donald PR, Schoeman JF, Van Zyl LE, De Villiers JN, Pretorius M, Springer P. Intensive short course chemotherapy in the management of tuberculosis meningitis. Int J Tuberc Lung Dis 1998; 2: 704-711. MEDLINE
    103. Girgis NI, Farid Z, Kilpatrick ME, Sultan Y, Mikhail IA. Dexamthasone adjunctive treatment for tuberculous meningitis. Pediatr Infect Dis J 1991; 10: 179-183. MEDLINE
    104. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculosis meningitis. Pediatrics 1997; 99: 226-231. CrossRef
    105. Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet 1987; 2: 1418-1422. MEDLINE
    106. Strang JI, Kakaza HH, Gibson DG, et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet 1998; 2: 759-764. MEDLINE
    107. Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart 2000; 84: 183-188.
    108. Lee CH, Wang WJ, Lan RS, Tsai YH, Chiang YC. Corticosteroids in the treatment of tuberculous pleurisy: a double-blind, placebo-controlled, randomized study. Chest 1988; 94: 1256-1259. MEDLINE
    109. Wyser C, Walzl G, Smedema JP, Swart F, Schalkwyk MV, Wal BW. Corticosteroids in the treatment of tuberculosis pleurisy: a double-blind, placebo-controlled, randomised study. Chest 1996; 110: 333-338. MEDLINE
    110. Dooley DP, Carpenter JL, Rademacher S. Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. Clin Infect Dis 1997; 25: 872-887. MEDLINE
    111. Brost BC, Newman RB. The maternal and fetal effects of tuberculosis therapy. Obstet Gynecol Clin North Am 1997; 24: 659-673. MEDLINE | CrossRef
    112. Valerio G, Bracciole P, Manisco V, Quitaderno M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxafloxacin therapy for tuberculosis: preliminary results. J Chemother 2003; 15: 66-70. MEDLINE
    113. American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108: 776-789.
    114. Peloquin CA. Antituberculosis drugs: pharmacokinetics In: , Heifets L, ed. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton: CRC Press, 1991: 59-88.
    115. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on cycloserine, ethionamide, paraaminosalicylate, and clofazimine. Chest 1999; 116: 984-990. MEDLINE | CrossRef
    116. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med 1999; 159: 1580-1584. MEDLINE
    117. Nunn P, Kibuga D, Gathua S, et al. Cutaneous hypersensitivity reactions due to thioacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991; 337: 627-630. MEDLINE
    118. Okwera A, Whalen C, Byekwaso F, et al. Randomised trial of thioacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 1994; 344: 1323-1328. MEDLINE | CrossRef
    119. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on mortality of patients treated for tuberculosis in a cohort study in Zambia. Trans R Soc Trop Med Hyg 1995; 89: 78-82. MEDLINE | CrossRef
    120. Harries AD. Tuberculosis in Africa: clinical presentation and management. Pharmacol Ther 1997; 73: 1-50. MEDLINE | CrossRef
    121. Alpert PL, Munsiff SS, Gourevitch MN, Greenberg B, Klein RS. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Clin Infect Dis 1997; 24: 661-668. MEDLINE
    122. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159: 733-740. MEDLINE
    123. Alwood K, Keruly J, Moore-Rice K, Stanton DL, Chaulk CP, Chaisson RE. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV infected patients. AIDS 1994; 8: 1103-1108. MEDLINE
    124. Driver DR, Munsiff SS, Li J, Kundamal N, Osahan SS. Relapse in persons treated for drug-susceptible tuberculosis in a population with high co-infection with human immunodeficiency virus in New York City. Clin Infect Dis 2001; 33: 1762-1769. MEDLINE
    125. Elliott AM, Halwiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on response to treatment and recurrence rate in patients treated for tuberculosis: two-year follow-up of a cohort in Lusaka, Zambia. J Trop Med Hyg 1995; 98: 9-21. MEDLINE
    126. Mallory KF, Churchyard GJ, Kleinschmidt I, De Cock KM, Corbett EL. The impact of HIV infection on recurrence of tuberculosis in South African gold miners. Int J Tuberc Lung Dis 2000; 4: 455-462. MEDLINE
    127. Connolly C, Reid A, Davies G, Sturm W, McAdam K, Wilkinson D. Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 1999; 13: 1543-1547. MEDLINE
    128. Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6 month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13: 1899-1904. MEDLINE
    129. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001; 358: 1687-1693. Abstract | Full Text | PDF (96 KB) | MEDLINE
    130. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999; 28: 419-430. MEDLINE
    131. Gonzalez-Montaner LJ, Natal S, Youngchaiyud P, Olliaro P. Rifabutin for the treatment of newly diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus rifampicin. Tuberc Lung Dis 1994; 75: 341-347.
    132. Schwander S, R?sch-Gerdes S, Mateega A, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. Tuberc Lung Dis 1995; 76: 210-218.
    133. McGregor MM, Olliaro P, Wolmarans L, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154: 1462-1467. MEDLINE
    134. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep 1998; 47 (RR-20): 1-58. MEDLINE
    135. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001; 164: 7-12. MEDLINE
    136. Munsiff SS, Fujiwara PI. Treatment of tuberculosis in patients taking antiretrovirals [erratum AIDS Reader 2000; 10: 206]. AIDS Reader 2000; 10: 102-108.
    137. Notice to readers: acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR Morb Mortal Wkly Rep 2002; 51: 214-215. MEDLINE
    138. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-1847. Abstract | Full Text | PDF (100 KB) | MEDLINE
    139. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-161. MEDLINE
    140. Wendel KA, Alwood K, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001; 120: 193-197. MEDLINE
    141. Chambers ST, Hendrickse WA, Record C, Rudge P, Smith H. Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet 1984; 2: 181-184. MEDLINE
    142. Wendland T, Furrer H, Vernazza PL, et al. HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. AIDS 1999; 13: 1857-1862. MEDLINE
    143. Navas E, Martin-Davila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162: 97-99. MEDLINE
    144. Frieden TR, Sherman LF, Maw KL, et al. A multi-institutional outbreak of highly drug resistant tuberculosis. JAMA 1996; 276: 1229-1235. MEDLINE
    145. World Health Organization Global Tuberculosis Programme. An expanded DOTS framework for effective tuberculosis control (WHO/CDS/TB/2002.297). Geneva: WHO, 2002:.
    146. World Health Organization. 44th World Health Assembly (WHA44/1991/REC/1); supplemented by 53rd World Health Assembly, Report by the Director General, Provisional Agenda Item 12.1, A53/5; May 5, 2000.
    147. Dye C, Watt CJ, Bleed DM, Williams BG. What is the limit to case detection under the DOTS strategy for tuberculosis control?. Tuberculosis 2003; 83: 35-43. Abstract | Full Text | PDF (116 KB) | MEDLINE
    148. Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Lancet 1998; 352: 1886-1891. Abstract | Full Text | PDF (81 KB) | MEDLINE
    149. Dye C. Tuberculosis 2000?2010: control, but not elimination. Int J Tuberc Lung Dis 2000; 4: S146-S152.
    150. Su?rez P, Watt CJ, Alarcon E, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis 2001; 184: 473-478. MEDLINE
    151. Dye C, Fengzeng Z, Scheele S, Williams B. Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China. Int J Epidemiol 2000; 29: 558-564. MEDLINE
    152. Khatri GR, Frieden TR. Controlling tuberculosis in India. N Engl J Med 2002; 347: 1420-1425.
    153. Jones JL, Hanson DL, Dworkin MS, DeCock KM. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. Int J Tuberc Lung Dis 2000; 4: 1026-1031. MEDLINE
    154. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064. Abstract | Full Text | PDF (105 KB) | MEDLINE
    155. Fine PEM. BCG vaccines and vaccination In: Reichman LB, Hershfield ES, eds. Tuberculosis: a comprehensive international approach. New York: Marcel Dekker, 2000: 503-522.
    156. World Health Oraganization. Core information for the development of immunization policy: 2002 update (WHO/V&B/02.28). Geneva: WHO, 2002:.
    157. Styblo K. Epidemiology of tuberculosis (selected papers). The Hague: Royal Netherlands Tuberculosis Association (KNCV), 1991:.
    158. Lotte A, Wasz-Hockert O, Poisson N. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 1988; 63: 47-59. MEDLINE
    159. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?. Int J Tuberc Lung Dis 1999; 3: 847-850. MEDLINE
    160. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137: 640-647.
    161. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations?United States. MMWR Morb Mortal Wkly Rep 2001; 50: 733-735. MEDLINE
    162. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002; 51: 998-999. MEDLINE
    163. Wilkinson D, Squire SB, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo-controlled trials. BMJ 1998; 317: 625-629. MEDLINE
    164. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15: 2137-2147. MEDLINE
    165. Quigley MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15: 215-222. MEDLINE
    166. Murray CJ, DeJonghe E, Chum HJ, Nyangulu DS, Salomao A, Styblo K. Cost effectiveness of chemotherapy for pulmonary tuberculosis in three sub-Saharan African countries. Lancet 1991; 338: 1305-1308. MEDLINE
    Back to top

    <!--end tail-->Affiliations

    a. New York City Department of Health and Mental Hygiene, New York, NY, USA
    b. Center for Tuberculosis Research, Johns Hopkins University School of Medicine, and Baltimore City Health Department Eastern Chest Clinic, Baltimore, MD
    c. Centers for Disease Control and Prevention, Atlanta, GA
    d. Communicable Diseases, WHO, Geneva, Switzerland


    • #3
      Figure 1

      Figure 1. Estimated number of new tuberculosis cases by country, 2001


      • #4
        Figure 2

        Figure 2. Trends and projections in numbers of tuberculosis cases to 2010 for countries of eastern and southern Africa with high HIV prevalence, and in the former Soviet Union
        Broken lines indicate 95% CI. Adapted with permission from WHO global tuberculosis report 2003, based on trends in notification rates.<!--start ce:cross-ref=--><!--start ce:sup=-->3


        • #5
          Table 1

          Table 1. WHO-recommended treatment regimens

          <!--start ce:table-footnote=-->
          *<!--start ce:note-para=-->Subscript after letters refers to the number of doses per week; daily has no subscript. H=isoniazid; R=rifampicin; Z=pyrazinamide; S=streptomycin, E=ethambutol.<!--end ce:note-para--><!--end ce:table-footnote-->
          <!--start ce:table-footnote=-->
          ?<!--start ce:note-para=-->A continuation phase of 6 months of HE has a higher failure and relapse rate than a continuation phase of 4 months of HR but can be used for mobile patients and those with limited access to health services; the HE regimen can also be used concomitantly with antiretroviral treatment of HIV-infected patients.<!--end ce:note-para--><!--end ce:table-footnote-->
          <!--start ce:table-footnote=-->
          ?<!--start ce:note-para=-->CDC/ATS and BTS recommend treatment for such patients based on susceptibility testing, with regimens tailored to the susceptibility profile. WHO recommends susceptibility testing whenever possible for patients with treatment failure.<!--end ce:note-para--><!--end ce:table-footnote-->
          <!--start ce:table-footnote=-->
          ?<!--start ce:note-para=-->WHO indicates that ethambutol need not be given in the initial phase of category III treatment if patients have non-cavitary, smear-negative pulmonary tuberculosis, or if patients are known to have a drug-susceptible organism, or for young children with primary tuberculos


          • #6
            Table 2

            Table 2. Doses, route of administration, and mode of action of primary drugs used in the treatment of tuberculosis

            Adapted with permission from the New York City Department of Health. Tuberculosis treatment, 3rd edn. City Health Information: 1999, 18 number 2 (available at IM=intramuscular; IV=intravenous; NR=not recommended.

            <!--start ce:table-footnote=-->
            *<!--start ce:note-para=-->Intravenous and suppository forms are available in some countries.<!--end ce:note-para--><!--end ce:table-footnote-->
            <!--start ce:table-footnote=-->
            ?<!--start ce:note-para=-->WHO, IUATLD, and BTS recommend 5 mg/kg in children; CDC/ATS and the American Academy of Pediatrics recommend 10 mg/kg.<!--end ce:note-para--><!--end ce:table-footnote-->
            <!--start ce:table-footnote=-->
            ?<!--start ce:note-para=-->WHO, IUATLD, and BTS recommend 10 mg/kg in children; CDC/ATS and the American Academy of Pediatrics recommend 10?20 mg/kg.<!--end ce:note-para--><!--end ce:table-footnote-->
            <!--start ce:table-footnote=-->
            ?<!--start ce:note-para=-->WHO and CDC/ATS recommend dosing of pyrazinamide in adults on a weight basis, but dosing based on weight categories as recommended by BTS and by tuberculosis programmes is more useful in practice. Recommendations of dosing for this drug vary widely. Adults weighing <45 kg can have paediatric doses. The doses given here are based on the New York City Tuberculosis Control Program.


            • #7
              Table 3

              Table 3. Major adverse reactions and recommended regular monitoring of primary drugs used in the treatment of tuberculosis

              Not all toxicities are listed here. Full prescribing information should be checked in the package insert or pharmacology texts.


              • #8
                Table 4

                Table 4. Reserve drugs used in the treatment of tuberculosis: doses, major adverse reactions, and recommended regular monitoring

                Adapted with permission from the New York City Department of Health. Tuberculosis treatment, 3rd edn. City Health Information: 1999, 18 number 2 (available at

                <!--start ce:table-footnote=-->
                *<!--start ce:note-para=-->Not all toxicities are listed here. Full prescribing information should be checked in the package insert or pharmacology texts.<!--end ce:note-para--><!--end ce:table-footnote-->
                <!--start ce:table-footnote=-->
                ?<!--start ce:note-para=-->WHO-recommended daily maximum doses are 750 mg for cycloserine, ethionamide, and protionamide.<!--end ce:note-para--><!--end ce:table-footnote-->
                <!--start ce:table-footnote=-->
                ?<!--start ce:note-para=-->Including protease inhibitors, non-nucleoside reverse transcriptase inhibitors, dapsone, ketoconazole, and oral contraceptives.<!--end ce:note-para--><!--end ce:table-footnote-->
                <!--start ce:table-footnote=-->
                ?<!--start ce:note-para=-->Contraindicated with saquinavir or delavirdine. See drug reference manuals for details on individual drugs.


                • #9
                  Table 5

                  Table 5. Use of antituberculosis drugs during pregnancy, tuberculous meningitis, and renal and hepatic failure

                  <!--start ce:table-footnote=-->
                  *<!--start ce:note-para=-->As with all medications given during pregnancy, antituberculosis medications should be used with extreme caution. The risk of tuberculosis to the fetus far outweighs the risk of most medications. Data are limited on the safety of antituberculosis medications during pregnancy. This table presents a consensus of published data and recommendations.<!--end ce:note-para--><!--end ce:table-footnote-->
                  <!--start ce:table-footnote=-->
                  ?<!--start ce:note-para=-->Steroid treatment seems to improve outcome in tuberculous meningitis, particularly in patients with altered mental status.<!--end ce:note-para--><!--end ce:table-footnote-->
                  <!--start ce:table-footnote=-->
                  ?<!--start ce:note-para=-->If possible, monitor serum drug concentrations of patients with renal insufficiency.<!--end ce:note-para--><!--end ce:table-footnote-->
                  <!--start ce:table-footnote=-->
                  ?<!--start ce:note-para=-->Supplement with pyridoxine (vitamin B6).<!--end ce:note-para--><!--end ce:table-footnote-->
                  <!--start ce:table-footnote=-->
                  ?<!--start ce:note-para=-->If an injectable medication must be used during pregnancy, streptomycin is preferred.<!--end ce:note-para--><!--end ce:table-footnote-->
                  <!--start ce:table-footnote=-->
                  <!--start ce:note-para=-->Has been used intrathecally; efficacy not documented.<!--end ce:note-para--><!--end ce:table-footnote-->
                  <!--start ce:table-footnote=-->
                  **<!--start ce:note-para=-->Avoid aminoglycosides and capreomycin in patients with reversible renal damage, if possible.


                  • #10
                    Figure 3

                    Figure 3. Observed and projected rate of detection of smear-positive cases compared with the 70% global target
                    The lower set of points is derived from case notifications submitted to WHO by DOTS programmes divided by the estimated incidence rate for these countries. Linear projection of the trend observed from 1995 to 2001 (blue line) indicates that, if the trend is maintained, 70% case detection will be reached in 2012. To reach 70% case detection by 2005, case finding must be significantly accelerated (red line). The upper set of points represent all smear-positive cases notified to WHO from all sources, including DOTS and non-DOTS programmes. Observations on the implementation of DOTS suggest that case-detection rates may reach a maximum of less than 50%, indicated by the broken line, unless case detection improves. Adapted with permission from Dye et al.<!--start ce:cross-ref=--><!--start ce:sup=-->147


                    • #11
                      Figure 4

                      Figure 4. Notified pulmonary tuberculosis cases per 100 000 population, Peru, 1980?2000
                      The DOTS strategy was introduced in 1990, and the incidence of pulmonary tuberculosis has been falling at an average of 6% per year since 1996. Adapted with permission from Su?rez et al.<!--start ce:cross-ref=--><!--start ce:sup=-->150